Skip to Content
Morningstar AustraliaMorningstar Australia
Market Centre
Market Report
Market Calendar
Discover Investments
Read the latest investing news and insights
Industry Insights
Investing content
Learn to invest in...
How to invest
Our research
Our Solutions
Featured Products and Services
The Company
Insights / Topics / MAYNE PHARMA
TOPIC

MAYNE PHARMA News & Analysis

Mayne Pharma woes to persist for 2020
Stocks
Mayne Pharma woes to persist for 2020
Morningstar had forecast big losses for the drugmaker, which has been dropped from the ASX 200.
Emma Rapaport | 15 June 2020
Hits and misses aplenty in first half 2020 - Part 2
Video
Hits and misses aplenty in first half 2020 - Part 2
Consumer stock Breville and listed property firm Charter Hall were among the highest gainers after delivering results, while Mayne Pharma and Seven...
Glenn Freeman | 10 March 2020
Positive outlook despite Mayne's $134m full-year loss
Stocks
Positive outlook despite Mayne's $134m full-year loss
The specialty drug-maker exceeded analysts' expectations on an adjusted basis, despite posting a full-year loss of $133.98 million.
Emma Rapaport | 24 August 2018